Demographic data of study population.
| Characteristics | Oligo Persistent, n = 28 | Oligo Extended, n = 15 | Poly RF-negative, n = 17 | Poly RF-positive, n = 4 | Systemic, n = 10 | All, n = 74 |
|---|---|---|---|---|---|---|
| Sex, girl (%) | 20 (71) | 12 (80) | 15 (88) | 4 (100) | 3 (30) | 54 (73) |
| Age, yrs, median (IQR) | 8.9 (7–11.8) | 12.8 (10–14) | 10.7 (9.5–14) | 13.9 (12–14.8) | 10.8 (7–13.3) | 11.3 (7–13.3) |
| Weight, kg, median (IQR) | 29.2 (23.2–40.7) | 43.0 (37.7–48.5) | 34.8 (27.5–51.9) | 48.7 (36.1–70) | 35.8 (20.5–65.2) | 35.7 (26.2–48.9) |
| Height, cm, median (IQR) | 136.5 (122–153) | 155 (145–167) | 143 (132–165) | 158 (154–162) | 146 (119–170) | 144 (130–163) |
| JADAS10, median (IQR) | 2.75 (1–6.5) | 3 (2–6) | 2 (1–5.5) | 4.25 (3.1–18.4) | 2 (1.3–4.3) | 2.5 (1–5) |
| ANA-positive (% of subtype) | 13 (46) | 8 (53) | 12 (71) | 3 (75) | 1 (10) | 37 (50) |
| BMI, median (IQR) | 16.2 (15.1–17.8) | 17.6 (15.8–19.1) | 16.6 (15.7–20.5) | 19.5 (15.2–26.7) | 16.9 (15.7–22.3) | 16.8 (15.6–19.4) |
| Disease duration, mos, median (IQR) | 36 (16.3–59.5) | 83 (60–134) | 51 (31–98.5) | 21 (9.8–36.5) | 55 (29.8–74.3) | 44 (28.8–86.3) |
| History of active knee, n (% of subtype) | ||||||
| Left | 17 (61) | 11 (73) | 12 (71) | 4 (100) | 3 (30) | 47 (64) |
| Right | 18 (64) | 12 (80) | 15 (88) | 4 (100) | 6 (60) | 55 (74) |
| IACI, n (% of active knees) | ||||||
| Left | 12 (71) | 10 (91) | 11 (92) | 4 (100) | 2 (67) | 39 (83) |
| Right | 15 (83) | 12 (100) | 14 (93) | 4 (100) | 4 (67) | 49 (89) |
| Treatment, n (% of subtype) | ||||||
| NSAID | 25 (89) | 9 (60) | 17 (100) | 4 (100) | 3 (30) | 58 (78) |
| Methotrexate | 4 (14) | 4 (27) | 8 (47) | 4 (100) | 3 (30) | 23 (31) |
| Biologics | 1 (4) | 6 (40) | 7 (41) | 1 (25) | 1 (10) | 16 (22) |
RF: rheumatoid factor; IQR: interquartile range; JADAS: Juvenile Arthritis Disease Activity Score; ANA: antinuclear antibodies; BMI: body mass index; IACI: intraarticular corticosteroid injection; NSAID: nonsteroidal antiinflammatory drug.